Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170060 | 0.87 | HDAC3 (0.63) | OGA | |
| SCHEMBL4807896 | 0.79 | HDAC3 (0.74) | HRH3 | |
| SCHEMBL4804346 | 0.79 | ALDH1A1 (0.61) | HRH3 | |
| SCHEMBL16048417 | 0.78 | HDAC3 (0.58) | OGAHRH3 | |
| SCHEMBL3159765 | 0.78 | HRH3 (0.54) | OGAHRH3 | |
| SCHEMBL4814724 | 0.77 | HDAC3 (0.53) | HRH3 | |
| SCHEMBL17541534 | 0.77 | OGA (0.83) | OGA | |
| SCHEMBL4815022 | 0.76 | HDAC3 (0.76) | HRH3 | |
| SCHEMBL20176409 | 0.76 | HRH3 (0.57) | OGAHRH3 | |
| SCHEMBL4859342 | 0.76 | SCD (0.51) | OGAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS | 2008-06-12 | — | — | US | disclosed |
| US-7345043-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS (US) | 2008-03-18 | — | — | US | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139535-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC10 | OGA 866/4885HRH3 313/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | OGA 866/4885HRH3 313/4885 |
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | OGA 866/4885HRH3 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.